Valeant Pharmaceuticals International Inc.’s merger talks with Actavis Inc. have stalled because of a disagreement on price, according to people familiar with the matter.
U.S. regulators, armed with a year- old Supreme Court decision, are stepping up probes of pharmaceutical deals that delay the sale of generic drugs, arrangements they view as illegally hurting competition.
Actavis Inc. agreed to sell assets covering four generic drugs in a settlement with U.S. regulators that clears the way for its $8.5 billion acquisition of Warner Chilcott Plc.
Ten years ago, Congress passed a law intended to penalize chief executive officers whose companies shift their legal addresses to tax havens.
Actavis Inc.’s generic version of the painkiller Fentora wouldn’t infringe two patents owned by Teva Pharmaceutical Industries Ltd.’s Cephalon unit, a U.S. appeals court ruled today.